Predictive and protective autoimmunity in cardiovascular diseases: is vaccination therapy a reality?

Abstract

The role of the immune system in modulating atherosclerosis has recently been well documented. Studies have revealed that cellular and humoral immunity plays crucial roles in atherogenic plaque formation. This includes macrophages, CD4+ T cells and dendritic cells as well as autoantigens such as oxidized low density lipoprotein (oxLDL), heat shock proteins and b2-glycoprotein I. Given these recent advances, various modifications of the immune system in experimental models have been proposed as therapeutic strategies, with the potential of inhibiting atherosclerosis progression. These modifications are switching the immune system (CD4+ T cells) from Th1 towards a Th2 anti-inflammatory cytokine secretion, and the induction of protective antibodies both of which may be induced by specific vaccination. Recent identification of specific immunoreactive antigenic epitopes on modified LDL, their successful implementation for immunization and the induction of atheroprotection, supports the idea that active vaccination may emerge as a novel immuno-modulating atheroprotective strategy.

Keywords

anti-oxLDL atherosclerosis protective autoimmunity vaccination

Get full access to this article

View all access options for this article.

References

Ehara S , Ueda M , Naruko T et al. Elevated levels of oxidized low density lipoprotein show a positive relationship with the severity of acute coronary syndrome . Circulation 2001; 103: 1955-1960 .

Matsura E , Kobayashi K , Koike T et al. Atherogenic autoantigen: oxidized LDL complexes with b2-glycoprotein I . Immunobiology 2003; 207: 17-22 .

Perschinka H , Mayr M , Millonig G et al. Crossreactive B-cell epitopes of microbial and human heat shock protein 60/65 in atherosclerosis . Arterioscler Thromb Vasc Biol 2003; 23: 1060-1065 .

Palinski W , Ord VA , Plump AS et al. ApoE-deficient mice are a model of lipoprotein oxidation in atherogenesis: demonstration of oxidation specific epitopes in lesions and high titers of autoantibodies to malondialdehyde-lysine in serum . Arterioscler Thromb 1994; 14: 605-616 .

Toshima S , Hasegawa A , Kurabayashi M et al. Circulating oxidized low density lipoprotein levels: a biochemical risk marker for coronary heart disease . Arterioscler Thromb Vasc Biol 2000; 20: 2243-2247 .

Hahn BH. Mechanisms of disease: antibodies to DNA . N Eng J Med 1998; 338: 1359-1368 .

Salonen JT , Yla-Hertualas , Yamamoto R et al. Autoantibody against oxidized LDL and progression of carotid atherosclerosis . Lancet 1992; 339: 883-887 .

Lippy P. Inflammation in atherosclerosis . Nature 2002; 420: 868-874 .

Boes M. Role of natural and immune IgM antibodies in immune responses . Mol Immunol 2000; 37: 1141-1149 .

10.

Stahl D , Sibrowski W. Regulation of the immune response by natural IgM: lessons from warm autoimmune hemolytic anemia . Curr Pharm Des 2003; 9: 1871-1880 .

11.

Oppezzo P , Dighiero G. Autoantibodies, tolerance and autoimmunity . Pathol Biol 2003; 51: 297-304 .

12.

Forger F , Matthias T , Oppermann M , Becker H , Helmke K. Clinical significance of anti-ds DNA antibody isotypes: IgG/IgM ratio of anti-dsDNA antibodies as a prognostic marker for lupus nephritis . Lupus 2004; 13: 36-44 .

13.

Werwitzke S , Trick D , Kamino K , Matthias T , Kniesch K , Schlegelberger B. Treatment of murine SLE with IgM anti-dsDNA autoantibodies. In Conrad K , Bachman P , Chan EKL et al. eds. From animal models to human genetics; research on the induction and pathogenicity of autoantibodies. Berlin, Germany: PABST Science Publ , 2004: 107-109.

14.

Shaw PX , Horkko S , Chang M-K et al. Natural antibodies with the T15 idiotype may act in atherosclerosis, apoptotic clearance, and protective immunity . J Clin Invest 2000; 105: 1731-1740 .

15.

Shoenfeld Y , Wu R , Dearing L , Matsuura E. Are anti-oxidized low-density lipoprotein antibodies pathogenic or protective ? Circulation 2004; 110: 2552-2558 .

16.

Palinski W , Horkko S , Miller E et al. Cloning of monoclonal autoantibodies to epitopes of oxidized lipoproteins from apoE2=2 mice. Demonstration of epitopes of oxLDL in human plasma . J Clin Invest 1996; 98: 800-814 .

17.

Fukumoto M , Shoji T , Emoto M et al. Antibodies against oxidized LDL and carotid artery intima-media thickness in a healthy population . Arterioscler Thromb Vasc Biol 2000; 20: 703-707 .

18.

Monaco C , Crea F , Niccoli G et al. Autoantibodies against oxidized low density lipoproteins in patients with stable angina, unstable angina, or peripheral vascular disease: pathophysiological implications . Eur Heart J 2000; 22: 1572-1577 .

19.

Frostegard J , Kjellman B , Gidlund M et al. Induction of heat shock protein in monocytic cells by oxidized low density lipoprotein . Atherosclerosis 1996; 121: 93-103 .

20.

Mayr M , Metzler B , Keichl S et al. Endothelial ctotoxicity mediated by serum antibodies to heat shock proteins of Escherichia coli and Chlamydia pneumoniae: immune reactions to heat shock proteins as a possible link between infection and atherosclerosis . Circulation 1999; 99: 1560-1566 .

21.

Vink A , Poppen M , Schoneveld AH et al. Distribution of Chlamydia pneumoniae in the human arterial system and its relation to the local amount of atherosclerosis within the individual . Circulation 2001; 103: 1613-1617 .

22.

George J , Harats D , Gilburd B et al. Immunolocalization of beta2- glycoprotein I (apolipoprotein H) to human atherosclerotic plaques: potential implications for lesion progression . Circulation 1999; 99: 2227-2230 .

23.

Sherer Y , Tenenbaum A , Praprotnik S et al. Coronary artery disease but not coronary calcification is associated with elevated levels of cardiolipin, beta2-glycoprotein I, and oxidized LDL antibodies . Cardiology 2001; 95: 20-24 .

24.

Ross R. Atherosclerosis - an inflammatory disease . N Eng J Med 1999; 340: 115-126 .

25.

Zhou X , Caligiuri G , Hamsten A , Lefvert AK , Hansson GK. LDL immunization induces T-cell independent antibody formation and protection against atherosclerosis . Arterioscler Thromb Vasc Biol 2001; 21: 108-114 .

26.

Iughetti L , Volta C , Maggi E et al. Circulating antibodies recognizing oxidatively modified low-density lipoprotein in children . Pediatr Res 1999; 45: 95-99 .

27.

Shoji T , Nishizawa Y , Fukumoto M et al. Inverse relationship between circulating oxidized low density lipoprotein (osLDL) and anti-oxLDL antibody levels in healthy subjects . Atherosclerosis 2000; 148: 171-177 .

28.

Ameli S , Hultgardh-Nilsson A , Regnstrom J et al. Effect of immunization with homologous LDL on early atherosclerosis in hypercholesterolemic rabbits . Arterioscler Thromb Vasc Biol 1996; 16: 1074-1079 .

29.

Sherer Y , Shoenfeld Y. Immunomodulation for treatment and prevention of atherosclerosis . Autoimmun Rev 2002; 1: 21-27 .

30.

Hansson GK. Vaccination against atherosclerosis . Circulation 2002; 106: 1599-1601 .

31.

Moon BG , Takaki S , Miyake K , Takatsu K. The role of IL-5 for mature B-1 cells in homeostatic proliferation, cell survival, and Ig production . J Immunol 2004; 172: 6020-6029 .

32.

Binder CJ , Hartivigsen K , Chang MK et al. IL-5 links adaptive and natural immunity specific for epitopes of oxidized LDL and protects from atherosclerosis . J Clin Invest 2004; 114: 427-437 .

33.

Kopf M , Brombacher F , Hodkin PD et al. IL-5-deficient mice have a developmental defect in CD5+ B-1 cells and lack of eosinophilia but have normal antibody and cytotoxic T cell responses . Immunity 1996; 4: 15-24 .

34.

Fredrikson GN , Soderberg I , Lindholm M et al. Inhibition of atherosclerosis in ApoE-null mice by immunization with ApoB-100 peptide sequences . Arterioscler Thromb Vasc Biol 2003; 23: 879-884 .

35.

Zhou X , Hansson G. Vaccination and atherosclerosis . Curr Atheroscler Rep 2004; 6: 158-164 .

36.

Schipou A , Bengtsson J , Soderberg I et al. Recombinant human antibodie against aldehyde-modified apolipoprotein B-100 peptide sequences inhibit atherosclerosis . Circulation 2004; 110: 2047-2052 .

37.

Shah PK , Chyu K-Y , Fredrikson GN , Nilsson J. Vaccination for atherosclerosis: a novel therapeutic paradigm . Expert Rev Vaccines 2004; 3: 1-6 .

38.

Nicolo D , Monestier M. Antiphospholipid antibodies and atherosclerosis . Clin Immunol 2004; 112: 183-189 .

39.

George J , Yacov N , Breitbart E et al. Suppression of early atherosclerosis in LDL-receptor deficient mice by oral tolerance with b2-glycoprotein I . Cardiovascular Research 2004; 62: 603-609 .

40.

Ohashi R , Mu H , Yao Q , Chen C. Atherosclerosis: immunopathogensis and immunotherapy . Med Sci Monit 2004; 10: 255-260 .

41.

Mandal K , Jahangiri M , Xu Q. Autoimmunity to heat shock proteins in atherosclerosis . Autoimmun Rev 2004; 3: 31-37 .

42.

Rittershaus CW , Miller DP , Thomas LJ et al. Vaccine-induced antibodies inhibit CETP activity in vivo and reduce aortic lesions in a rabbit model of atherosclerosis . Arterioscler Thromb Vasc Biol 2000; 20: 2106-2112 .

43.

Davidson MH , Maki K , Umporowicz D et al. The safety and immunogenicity of a CETP vaccine in healthy adults . Artherosclerosis 2003; 169: 113-120 .